AlleyCorp raises $335M second fund, bets early on unfashionable ideas

AlleyCorp's $335 million（約540億円） second fund arrives in a venture landscape fundamentally reshaped by AI funding concentration. Ryan's framing is revealing: he notes that $412.7 billion（約66兆円） in U.S. venture dollars in 2026 so far has flowed into just a few companies, with tens of billions pouring into Anthropic and OpenAI. He explicitly argues these are no longer venture capital but a distinct asset class larger than public companies—a shift that redefines what "venture" means at scale. His earlier example of DoubleClick (which he sold for $1.1 billion（約1800億円） in 2005) illustrates the point: if founded today, it would remain private far longer and exit at a $10 billion（約1.6兆円） valuation, yet the mega-rounds into AI-first companies reach $1 trillion（約160兆円） and are still labeled "VC money."

This positions AlleyCorp's strategy as a deliberate counter-current. By doubling down on first checks under $10 million（約16億円） and early-stage bets where "it's not obvious," Ryan is betting that value creation will persist in overlooked areas. His psychedelics example—moving from skepticism to backing the Yale Center for Psychedical Research and cofounding Transcend Therapeutics, which sold for $1.2 billion（約1900億円） in June—demonstrates his willingness to shift conviction on contrarian theses when data emerges. The firm's portfolio of eight unicorns (Rogo, ShopMy, Valar Atomics, Thyme Care) suggests the approach has worked, even as mega-rounds dominate headlines.

Ryan's openness to expanding the fund to $500–600 million through vertical (biotech) or geographic expansion signals confidence in the model without changing stage focus—a disciplined growth path distinct from the spray-and-pray dynamics of larger funds chasing AI scale.